Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Zelira Therapeutics ( (AU:ZLD) ) is now available.
Zelira Therapeutics Limited has announced a proposed issue of securities, specifically a convertible note, with a maximum of 580,271 securities to be issued. This move is part of their strategy to raise capital, potentially impacting the company’s financial position and market operations as they continue to expand their offerings in the cannabinoid-based medicine sector.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company targets various therapeutic areas, aiming to provide innovative solutions for patients and healthcare providers.
Average Trading Volume: 5,879
Technical Sentiment Signal: Sell
Current Market Cap: A$4.05M
Learn more about ZLD stock on TipRanks’ Stock Analysis page.